Coinfection with Hypervirulent Klebsiella pneumoniae and Aspergillus flavus in a Critically Ill Patient with Aspergillus Overlap Syndrome: A Case Report

References

• Cadena J, Thompson GR 3rd, Patterson TF. Aspergillosis: epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 2021;35(2):415–434. doi:10.1016/j.idc.2021.03.008
   PubMed Web of Science ®Google Scholar
• Li L, Jiang Z, Shao C. Pulmonary aspergillus overlap syndromes. Mycopathologia. 2018;183(2):431–438. doi:10.1007/s11046-017-0212-y
   PubMed Web of Science ®Google Scholar
• Yue R, Wu X, Li T, et al. Early detection of legionella pneumophila and aspergillus by mNGS in a critically Ill patient with legionella pneumonia after extracorporeal membrane oxygenation treatment: case report and literature review. Front Med. 2021;8:686512. doi:10.3389/fmed.2021.686512
   Web of Science ®Google Scholar
• Keown K, Reid A, Moore JE, et al. Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis. Eur Respir Rev. 2020;29(158):200011. doi:10.1183/16000617.0011-2020
   Web of Science ®Google Scholar
• Lai CC, Wang CY, Hsueh PR. Coinfections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505–512. doi:10.1016/j.jmii.2020.05.013
   PubMedGoogle Scholar
• Wang Q, Wang Z, Hao Y, et al. Coinfection with cryptococcus and aspergillus in an immunocompetent adult: a case report. Medicine. 2018;97(39):e12612. doi:10.1097/MD.0000000000012612
   Web of Science ®Google Scholar
• Enoki E, Maenishi O, Chikugo T, et al. Coinfection of Aspergillus and Cryptococcus in post-tuberculosis pulmonary cavity. Pathol Int. 2012;62:574–576. doi:10.1111/j.1440-1827.2012.02839.x
   Web of Science ®Google Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses. 2009;52(3):206–222. doi:10.1111/j.1439-0507.2008.01642.x
   PubMed Web of Science ®Google Scholar
• Maturu VN, Agarwal R. Acute invasive pulmonary aspergillosis complicating allergic bronchopulmonary aspergillosis: case report and systematic review. Mycopathologia. 2015;180(3–4):209–215. doi:10.1007/s11046-015-9907-0
   Web of Science ®Google Scholar
• Tang JH, Gao DP, Zou PF. Comparison of serum PCT and CRP levels in patients infected by different pathogenic microorganisms: a systematic review and meta-analysis. Braz J Med Biol Res. 2018;51(7):e6783. doi:10.1590/1414-431x20176783
   PubMed Web of Science ®Google Scholar
• Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4(2):107–118. doi:10.4161/viru.22718
   PubMed Web of Science ®Google Scholar
• Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001–e00019. doi:10.1128/CMR.00001-19
   PubMed Web of Science ®Google Scholar
• Russo TA, Olson R, Fang CT, et al. Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae. J Clin Microbiol. 2018;56(9):e00776–e00818. doi:10.1128/JCM.00776-18
   PubMed Web of Science ®Google Scholar
• Yan Q, Zhou M, Zou M, et al. Hypervirulent Klebsiella pneumoniae induced ventilator-associated pneumonia in mechanically ventilated patients in China. Eur J Clin Microbiol Infect Dis. 2016;35(3):387–396. doi:10.1007/s10096-015-2551-2
   PubMed Web of Science ®Google Scholar
• Hwang JH, Hwang JH, Lee SY, et al. Prostatic abscess caused by Klebsiella pneumoniae: a 6-year single-center study. J Clin Med. 2022;11(9):2521. doi:10.3390/jcm11092521
   Web of Science ®Google Scholar
• Lai CC, Yu WL. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect. 2021;54(1):46–53. doi:10.1016/j.jmii.2020.09.004
   Google Scholar
• Nogueira MF, Pereira L, Jenull S, et al. Klebsiella pneumoniae prevents spore germination and hyphal development of Aspergillus species. Sci Rep. 2019;9(1):218. doi:10.1038/s41598-018-36524-8
   Web of Science ®Google Scholar
• Orlopp K, von Lilienfeld-Toal M, Marklein G, et al. False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem? J Antimicrob Chemother. 2008;62(5):1109–1112. doi:10.1093/jac/dkn308
   Web of Science ®Google Scholar
• Metan G, Ağkuş C, Buldu H, et al. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. Infection. 2010;38(3):217–221. doi:10.1007/s15010-010-0003-6
   Web of Science ®Google Scholar
• Martín-Mazuelos E, Loza A, Castro C, et al. β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis. Intensive Care Med. 2015;41(8):1424–1432. doi:10.1007/s00134-015-3922-y
   Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Douglas AP, Smibert OC, Bajel A, et al. Australasian Antifungal Guidelines Steering Committee. Consensus guidelines for the diagnosis and management of invasive aspergillosis. 2021. Intern Med J. 2021;51(Suppl 7):143–176. doi:10.1111/imj.15591
   Web of Science ®Google Scholar
• Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transplant. 2016;30(11):1377–1386. doi:10.1111/ctr.12834
   PubMed Web of Science ®Google Scholar
• Elbey MA, Cil H, Onturk E, et al. QTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy. Eur Rev Med Pharmacol Sci. 2012;16(1):100–102.
   Web of Science ®Google Scholar
• Alkan Y, Haefeli WE, Burhenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis. 2004;39(6):e49–e52. doi:10.1086/423275
   Web of Science ®Google Scholar
• Mourad A, Stiber JA, Perfect JR, et al. Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. J Antimicrob Chemother. 2019;74(1):228–233. doi:10.1093/jac/dky392
   Web of Science ®Google Scholar
• Keçeli SA, Willke A, Tamer GS, et al. Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods. APMIS. 2014;122(5):412–417. doi:10.1111/apm.12159
   Web of Science ®Google Scholar